Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets September 29, 2023
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM June 5, 2023
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE March 14, 2023
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team March 8, 2023
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate March 1, 2023
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate December 22, 2022
